tiprankstipranks
Atea Pharmaceuticals Phase 3 SUNRISE-3 trial did not meet primary endpoint
PremiumThe FlyAtea Pharmaceuticals Phase 3 SUNRISE-3 trial did not meet primary endpoint
3M ago
Atea Pharma publishes data on metabolic activation pathway of bemnifosbuvir
Premium
The Fly
Atea Pharma publishes data on metabolic activation pathway of bemnifosbuvir
4M ago
Atea Pharmaceuticals upgraded to Equal Weight from Underweight at Morgan Stanley
Premium
The Fly
Atea Pharmaceuticals upgraded to Equal Weight from Underweight at Morgan Stanley
4M ago
Atea Pharmaceuticals announces presentation on safety profile of bemnifosbuvir
PremiumThe FlyAtea Pharmaceuticals announces presentation on safety profile of bemnifosbuvir
8M ago
Atea Pharmaceuticals completes patient enrollment in Phase 3 SUNRISE-3 trial
Premium
The Fly
Atea Pharmaceuticals completes patient enrollment in Phase 3 SUNRISE-3 trial
9M ago
Atea Pharmaceuticals reports Q4 EPS (47c), consensus (51c)
Premium
The Fly
Atea Pharmaceuticals reports Q4 EPS (47c), consensus (51c)
10M ago
Atea Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
PremiumThe FlyAtea Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
1y ago
Atea Pharmaceuticals reports Q2 EPS (34c), consensus (47c)
Premium
The Fly
Atea Pharmaceuticals reports Q2 EPS (34c), consensus (47c)
1y ago
Atea announces first patient dosed in Phase 2 study of bemnifosbuvir, ruzasvir
Premium
The Fly
Atea announces first patient dosed in Phase 2 study of bemnifosbuvir, ruzasvir
2y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100